Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 5 points (0.0%) at 17,667 as of Monday, Jan. 26, 2015, 12:05 PM ET. The NYSE advances/declines ratio sits at 1,760 issues advancing vs. 1,190 declining with 185 unchanged.

The Health Services industry currently sits up 0.4% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include

Brookdale Senior Living

(

BKD

), down 10.0%,

Anthem

(

ANTM

), down 1.1% and

Stryker Corporation

(

SYK

), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Baxter International

(

BAX

) is one of the companies pushing the Health Services industry lower today. As of noon trading, Baxter International is down $0.49 (-0.7%) to $70.94 on average volume. Thus far, 1.5 million shares of Baxter International exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $70.78-$71.56 after having opened the day at $71.42 as compared to the previous trading day's close of $71.43.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $39.2 billion and is part of the health care sector. Shares are down 2.5% year-to-date as of the close of trading on Friday. Currently there are 3 analysts that rate Baxter International a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Baxter International

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Baxter International Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

Covidien

TST Recommends

(

COV

) is down $0.93 (-0.9%) to $107.14 on heavy volume. Thus far, 3.8 million shares of Covidien exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $107.06-$108.16 after having opened the day at $107.97 as compared to the previous trading day's close of $108.07.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The company operates through Medical Devices and U.S. Medical Supplies segments. Covidien has a market cap of $48.2 billion and is part of the health care sector. Shares are up 5.7% year-to-date as of the close of trading on Friday. Currently there are 5 analysts that rate Covidien a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates

Covidien

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Covidien Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Medtronic

(

MDT

) is down $1.54 (-2.0%) to $75.41 on heavy volume. Thus far, 7.3 million shares of Medtronic exchanged hands as compared to its average daily volume of 7.5 million shares. The stock has ranged in price between $75.34-$76.93 after having opened the day at $76.87 as compared to the previous trading day's close of $76.95.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. Medtronic has a market cap of $74.3 billion and is part of the health care sector. Shares are up 6.6% year-to-date as of the close of trading on Friday. Currently there are 14 analysts that rate Medtronic a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Medtronic

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Medtronic Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health services industry could consider

ProShares Ultra Short Health Care

(

RXD

).

null